[1] 吕桂善,霍贵成.乳及乳制品中的抗高血压活性肽[J].中国乳品工业,2002,30(5):53-56.[2] 何海伦,陈秀兰,孙彩云,张玉忠.血管紧张素转化酶抑制肽的研究进展[J]. 中国生物工程杂志,2004,24(9):7-11.[3] Saito T. Antihypertensive Peptides Derived from Bovine Casein and Whey Proteins [J].Bioactive Components of Milk,2008, 12:295-317.[4] 毛慧, 蔡炳锋, 赵波, 等. 5-硝基-1H-吲哚-2-羧酸与牛血红蛋白相互作用的分子模拟与光谱研究[J]. 化学研究与应用, 2009, 21(5): 675-679.[5] 毛慧, 蔡炳锋, 赵波, 等. 苏丹红Ⅱ与肌红蛋白相互作用的分子模拟与实验[J]. 应用化学, 2009, 26(11): 1332-1335.[6] Pina AS, Roque AC. Studies on the molecular recognition between bioactive peptides and angiotensinconverting enzyme [J]. Mol Recognit, 2009, 22(2): 162-168.[7] 赵钰岚, 许传莲. 血管紧张素转换酶的结构功能及相关抑制剂[J]. 生物工程学报, 2008, 24(2): 171-176.[8] 王伟, 沈生荣, 冯凤琴, 等. 基于药效团的血管紧张素转换酶抑制肽的结构优化[J]. 中国科学, 2008, 38(4): 357-364.[9] 郑清川, 楚慧郢, 牛瑞娟, 等. 人类乙酰胆碱酯酶(AChE)与抑制剂小分子的对接研究[J]. 中国科学B辑: 化学, 2009, 39(11): 1454-1460.[10] Englebienne P, Moitessier N.Docking Ligands into Flexible and Solvated Macromolecules.Are Popular Scoring Functions Accurate for this Class of Proteins [J]. J. Chem. Inf. Model, 2009, 49(6): 1568-1580.[11] Montes M, Miteva M A, Villoutreix B O. Structure-based virtual ligand screening with LigandFit: Pose prediction and enrichment of compound collections [J]. Proteins: Struct.Funct.Bioinf, 2007, 68(3): 712-725.[12] Taha M O, AlDamen M A. Effects of variable docking conditions and scoring functions on corresponding protein-aligned comparative molecular field analysis models constructed from diverse human protein tyrosine phosphatase 1B inhibitors [J]. J. Med. Chem, 2005, 48(25): 8016-8034.[13] Laberge M, Kovesi I, Yonetani T, et al. R-state hemoglobin bound to heterotropic effectors: models of the DPG, IHP and RSR13 binding sites [J]. FEBS Lett, 2005, 579(3): 627-632. [14] 张艳,胡志和. 乳蛋白源ACE 抑制肽的研究进展[J].食品科学,2008,29(10):634-639.[15] Zhao YH, Li BF, Liu ZY, et al.Antihypertensive effect and purification of an ACE inhibitory peptide from sea cucumber gelatin hydrolysate[J]. Process Biochemistry, 2007, 42: 1586-1591.[16] David W O, Norman H N. Princiciples of modern chemistry [M]. 1986.[17] Natesh R, Schwager SLU, Sturrock ED, Acharya KR. Crystal structure of the human angiotensin-converting enzyme-lisinopril complex [J].Nature, 2003, 421: 551–554.[18] Kim HM, Shin DR, Yoo OJ, Lee H, Lee J. Crystal structure of Drosophila angiotensin I-converting enzyme bound to captopriland lisinopril[J].FEBS Lett, 2003, 538: 65–70.[19] Tzakos AG, Gerothanassis IP. Domain-selective ligand-binding modes and atomic level pharmacophore refinement in angiotensin I-converting enzyme (ACE) inhibitors [J].ChemBioChem,2005, 6: 1089–1103.[20] Natesh R, Schwager SLU, Evans HR, Sturrock ED, Acharya KR. Structural details on the binding of antihypertensive drug captopril and enalaprilat to human testicular angiotensin I-converting enzyme[J].Biochemistry,2004,43: 8718–8724.[21] Corradi HR, Chitapi I, Sewell BT, Georgiadis D, Dive V, Sturrock ED, Acharya KR. The structure of testis angiotensin-converting enzyme in complex with the C domain-specific inhibitor RXPA380 [J]. Biochemistry, 2007, 46: 5473–5478.[22] Andújar-Sánchez M, Cámara-Artigas A, Jara-Pérez V. A calorimetric study of the binding of lisinopril, enalaprilat and captopril to angiotensin-converting enzyme. Biophys[J].Chem,2004,111: 183–189. |